A. A. Alper Ozturk Et Al. , "Cefaclor Monohydrate-Loaded Colon-Targeted Nanoparticles for Use in COVID-19 Dependent Coinfections and Intestinal Symptoms: Formulation, Characterization, Release Kinetics, and Antimicrobial Activity," ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES , vol.19, no.3, pp.156-175, 2021
Alper Ozturk, A. A. Et Al. 2021. Cefaclor Monohydrate-Loaded Colon-Targeted Nanoparticles for Use in COVID-19 Dependent Coinfections and Intestinal Symptoms: Formulation, Characterization, Release Kinetics, and Antimicrobial Activity. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES , vol.19, no.3 , 156-175.
Alper Ozturk, A. A., Namli, I., & Aygül, A., (2021). Cefaclor Monohydrate-Loaded Colon-Targeted Nanoparticles for Use in COVID-19 Dependent Coinfections and Intestinal Symptoms: Formulation, Characterization, Release Kinetics, and Antimicrobial Activity. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES , vol.19, no.3, 156-175.
Alper Ozturk, AHMET, Irem Namli, And Abdurrahman Aygül. "Cefaclor Monohydrate-Loaded Colon-Targeted Nanoparticles for Use in COVID-19 Dependent Coinfections and Intestinal Symptoms: Formulation, Characterization, Release Kinetics, and Antimicrobial Activity," ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES , vol.19, no.3, 156-175, 2021
Alper Ozturk, AHMET A. Et Al. "Cefaclor Monohydrate-Loaded Colon-Targeted Nanoparticles for Use in COVID-19 Dependent Coinfections and Intestinal Symptoms: Formulation, Characterization, Release Kinetics, and Antimicrobial Activity." ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES , vol.19, no.3, pp.156-175, 2021
Alper Ozturk, A. A. Namli, I. And Aygül, A. (2021) . "Cefaclor Monohydrate-Loaded Colon-Targeted Nanoparticles for Use in COVID-19 Dependent Coinfections and Intestinal Symptoms: Formulation, Characterization, Release Kinetics, and Antimicrobial Activity." ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES , vol.19, no.3, pp.156-175.
@article{article, author={AHMET ALPER ÖZTÜRK Et Al. }, title={Cefaclor Monohydrate-Loaded Colon-Targeted Nanoparticles for Use in COVID-19 Dependent Coinfections and Intestinal Symptoms: Formulation, Characterization, Release Kinetics, and Antimicrobial Activity}, journal={ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES}, year=2021, pages={156-175} }